62,580 Shares in Intuitive Surgical, Inc. $ISRG Acquired by CIBC Bancorp USA Inc.

CIBC Bancorp USA Inc. bought a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the third quarter, Holdings Channel reports. The firm bought 62,580 shares of the medical equipment provider’s stock, valued at approximately $27,988,000.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Intuitive Surgical by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock worth $15,026,776,000 after buying an additional 263,828 shares during the last quarter. State Street Corp grew its stake in Intuitive Surgical by 1.2% in the 2nd quarter. State Street Corp now owns 15,552,203 shares of the medical equipment provider’s stock valued at $8,451,223,000 after buying an additional 182,871 shares during the last quarter. Capital World Investors raised its holdings in Intuitive Surgical by 1.5% in the 3rd quarter. Capital World Investors now owns 7,728,492 shares of the medical equipment provider’s stock worth $3,456,223,000 after acquiring an additional 116,034 shares during the period. Norges Bank bought a new position in Intuitive Surgical in the 2nd quarter worth $2,569,260,000. Finally, Invesco Ltd. lifted its position in Intuitive Surgical by 4.8% during the 2nd quarter. Invesco Ltd. now owns 4,421,133 shares of the medical equipment provider’s stock worth $2,402,488,000 after acquiring an additional 201,159 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several recent analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Intuitive Surgical in a research note on Monday, December 29th. Raymond James Financial lifted their price target on Intuitive Surgical from $603.00 to $615.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Evercore reduced their price objective on Intuitive Surgical from $580.00 to $550.00 and set an “in-line” rating for the company in a research report on Friday, January 23rd. Piper Sandler restated an “overweight” rating and issued a $620.00 price objective (up from $610.00) on shares of Intuitive Surgical in a research note on Friday, January 23rd. Finally, Royal Bank Of Canada boosted their target price on shares of Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average price target of $614.95.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Company fundamentals and market positioning — Intuitive reported a strong January quarter (beats on revenue and EPS, ~19% revenue growth year‑over‑year) and is pursuing lower‑cost da Vinci systems to target fast‑growing ambulatory surgery centers, which could expand procedure volume outside hospitals over time. No external link
• Neutral Sentiment: Sector and competitive news with limited direct impact — other medtech product launches and approvals in the broader ecosystem (e.g., Merit Medical’s new esophageal stent) are being reported but do not directly displace Intuitive’s robotic surgery franchise. MMSI Launches Resilience TTS Stent for Esophageal Fistulas, Strictures
• Negative Sentiment: FDA regulatory flag — Intuitive was flagged by the FDA over a medical device issue, which raises near‑term regulatory and operational risk concerns; such notices can prompt customer caution, warranty/repair costs, or increased oversight that pressure sentiment. Intuitive Surgical flagged by FDA over medical device issue
• Negative Sentiment: Analyst outlook softened — UBS cut its price target from $570 to $550 and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure; the new target still implies some upside versus current levels but reflects more cautious sentiment. Intuitive Surgical (NASDAQ:ISRG) Price Target Lowered to $550.00 at UBS Group

Insiders Place Their Bets

In related news, EVP Myriam Curet sold 421 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total value of $208,378.16. Following the completion of the transaction, the executive vice president directly owned 409 shares in the company, valued at approximately $202,438.64. This represents a 50.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mark Brosius sold 2,362 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $498.68, for a total value of $1,177,882.16. Following the completion of the transaction, the senior vice president directly owned 3,554 shares of the company’s stock, valued at approximately $1,772,308.72. This trade represents a 39.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 32,943 shares of company stock valued at $17,279,568 in the last ninety days. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Stock Down 1.0%

Shares of ISRG opened at $477.73 on Thursday. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $603.88. The firm has a market capitalization of $169.66 billion, a price-to-earnings ratio of 60.55, a P/E/G ratio of 3.72 and a beta of 1.66. The stock’s 50-day moving average price is $507.10 and its 200 day moving average price is $512.85.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The firm had revenue of $2.87 billion during the quarter, compared to analysts’ expectations of $2.72 billion. During the same quarter in the prior year, the firm posted $2.21 EPS. The company’s revenue for the quarter was up 18.8% on a year-over-year basis. Equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.